RISK-OFF Oil above $90, a 4.79% U.S. 10-year yield, falling U.S./Asian equities and a −20% post-close CRDO indication outweigh isolated relative strength.
Generated 08:36:38 CEST (Europe/Rome) / 06:36:38 UTC. Data cutoff about 08:31 CEST. Asian values are Sep. 2 latest/near-close; U.S. cash and European values are Sep. 1 closes. Futures are overnight indications around 08:23 CEST. At 08:30 Italy, European cash markets have not opened and U.S. cash trading/many U.S. releases are hours away.
*FTSE change uses adjacent daily closes; Yahoo intraday metadata supplied a conflicting −0.03% field, which is not used.
Reuters reports fresh U.S.–Iran strikes and retaliation; WTI extended to $90.79. The official Treasury curve moved to 4.39% at 2Y and 4.79% at 10Y. This raises inflation and discount-rate risk simultaneously. Reuters discovery · Treasury · WTI
Russell −1.23%, Nasdaq −1.03%, Nikkei −2.78%, Hang Seng −1.27% and Shanghai −0.75%; all four U.S. futures were negative. VIX rose 9.52% to 16.34—higher, but not panic territory. Russell · Nikkei
CRDO's official release reported $479.0M revenue (+114.7% YoY), yet shares indicated $185.72 after hours, −20.21% from the prior close. Broadcom reports after Wednesday's close, making guidance/margins the next ecosystem test. CRDO release · Nasdaq calendar
Risk class: large-cap enterprise cloud; post-earnings/high-volatility. Classification: relative-strength continuation. Applicable horizon: day trade and 1–4 week swing only after confirmation; 3–12+ months requires recurring-growth, margins and FCF review. Direction uncertain.
Thesis/catalyst: $258.11, +0.22%, while Nasdaq lost 1.03%; three closes above $256 preserve the earnings-gap structure.
Evidence / counterargument: Tuesday reached $262.32 and held $254.25. Counter: second rejection near $262, volume fell to 15.9M, the gap toward $230 remains open, and software post-close moves were sharply mixed.
Entry/confirmation: require a hold above $258 then close above $262.32 with software breadth. Invalidation/downside: close below $254; below $249 opens gap-fill risk toward $230. Key risks: rates, valuation, competition, execution, AI monetization quality and broad risk-off tape. price/volume
Risk class: high-beta AI connectivity; extreme post-earnings gap, concentration and valuation risk. Classification: avoid catching the gap; no blind short. Applicable horizon: day observation and 1–4 week base-building; 3–12+ months only after valuation, customer mix, margins and FCF review. Direction highly uncertain; short loss is unlimited.
Thesis/catalyst: regular close $206.63, −8.65%; post-close $185.72, −20.21% versus the prior close after official results. Q2 revenue outlook implies continued growth, but guided GAAP gross margin midpoint is below Q1.
Evidence / counterargument: price/volume confirm expectation reset; Q1 revenue +114.7% YoY and $764.3M cash/short investments are powerful counters and can cause a squeeze/reversal.
Entry/confirmation: avoid until post-report cash price discovery; bearish only after failed reclaim of $190 and break below the first regular-session low. Invalidation/downside: bearish thesis invalid above $206.63 on sustained volume; downside cannot be responsibly bounded before the open and gaps bypass stops. Risks: squeeze, liquidity, guidance interpretation, customer concentration, margins, AVGO read-through and rates; borrow/fees unknown. release · price
Risk class: newly listed de-SPAC quantum; extreme price-discovery/liquidity risk. Classification: avoid chasing; bearish only on failed reclaim. Applicable horizon: day observation; 1–4 weeks wait for structure; no 3–12+ month call without financial evidence. Direction highly uncertain; short loss is unlimited.
Thesis/catalyst: $15.56, −10.06%, after $12.73–17.50 range; prior report's below-$17 trigger fired, but no execution is claimed.
Evidence / counterargument: two consecutive declines from the $19.11 debut close on 1.87M shares confirm failed momentum. Counter: Tuesday recovered 22% from its low, float-driven moves can reverse violently, and neutral-atom milestones could add value.
Entry/confirmation: no blind short; require failed reclaim of $17 then loss of $15.50. Avoid is preferred. Invalidation/downside: bearish view invalid above $17.50; $13.08/$12.73 are downside references, not forecasts. Risks: minimal chart history, halts, float/warrants, dilution, squeeze and no verified operating metrics here; borrow/fees not sourced. price · listing filing
No second/third bullish or third bearish setup: risk-off breadth, $90.79 WTI, 4.79% 10Y and AVGO event risk do not justify filling quotas. The only bullish setup requires confirmation; waiting is valid.
Risk class: mega-cap semiconductor/infrastructure; event-gap, leverage and concentration risk. Classification/horizon: direction uncertain; no pre-event position; day/1–4 weeks after Sep. 2 price discovery; 3–12+ months only on guidance, margins and FCF.
Thesis/catalyst/evidence: $369.68, −0.18%, reports after close. Holding near $370 is relative resilience. Counter: AI expectations are high and CRDO's gap shows “good” growth can still disappoint.
Confirmation: post-report base above $371.40 then $376.59. Invalidation/downside: below $362 weakens, with $355.31 reference; event gaps bypass levels. Risks: custom-silicon/customer concentration, networking margins, integration/leverage, rates and export controls. calendar · price
Risk class: mega-cap semiconductor; high expectations/post-earnings volatility. Classification/horizon: direction uncertain; demoted repair watch; day/1–4 week swing after reclaim; 3–12+ months on sustained growth, margins and FCF.
Thesis/evidence: $217.44, −1.51%, held above $215.10 but lost $220. Counter: latest company release reported $96.2B Q2 revenue and $108B ±2% Q3 guidance, excluding China data-center compute; structural growth remains strong.
Confirmation: reclaim/close above $220.41, stronger above $225 with semiconductor breadth. Invalidation/downside: below $215.10 weakens; $209.23 reference. Risks: valuation, margins, China/export controls, capex/customer concentration, power constraints and rates. NVIDIA · price
Risk class: large-cap/high-beta AI power and cooling. Classification/horizon: direction uncertain; failed-repair watch; 1–4 weeks after confirmation; 3–12+ months on backlog, margins and FCF.
Thesis/evidence: $255.97, −1.06%; data-center power/cooling remains a structural theme, but price lost Monday's advance. Counter: five-day change +0.09% is better than quantum/peptide peers.
Confirmation: reclaim $258.72 then $261.79; stronger above $270. Invalidation/downside: below $254.91 weakens, with $245 reference. Risks: capex timing, execution, valuation, rates, inputs and power-project delays. price
Risk class: small-cap biotech; high binary/dilution risk. Classification/horizon: direction uncertain; evidence/base watch; no day chase; 1–4 weeks above confirmation; 3–12+ months only after full clinical, safety, cash-runway and regulatory review.
Thesis/evidence: $33.67, +2.72%, reclaimed $33. Counter: still below $34.39/$34.99 recent highs, five-day −1.46%, and no new trial catalyst was verified.
Confirmation: close above $33.71 then $34.39. Invalidation/downside: below $32.38, then $31.70; $30 reference. Risks: efficacy/tolerability statistics, runway not refreshed today, dilution, competition, manufacturing and regulatory path. 10-Q · price
Risk class: speculative quantum; extreme duration, dilution and capital-structure risk. Classification/horizon: direction uncertain; avoid-to-watch; day/1–4 weeks only after reclaim; 3–12+ months requires commercial/unit-economics proof.
Thesis/evidence: $37.78, −3.89%, below $38.43 and five-day −10.15%. Public-warrant cessation/expiry on Sep. 29/30 is date-certain. Counter: company/contract news and squeezes can reverse price rapidly.
Confirmation: reclaim $39.25 then $40.55. Invalidation/downside: below $37.59 weakens; no long setup. Risks: cash burn, dilution/warrants, architecture, commercialization, rates and volatility; borrow/fees unknown. 8-K · price
Confidence measures evidence quality, never guaranteed outcome probability. Risk is higher when riskier; Opportunity incorporates setup quality after risk.
Bias: defensive; only confirmed CRM strength. Do not catch CRDO before cash price discovery or front-run AVGO.
Biggest risk: conflict/oil headlines and earnings gaps. Invalidation: caution eases only if WTI reverses, yields fall and semis/Russell reclaim Tuesday ranges together.
Bias: cash-heavy; wait for AVGO/FOMC evidence. AI infrastructure can be revisited after bases; quantum remains avoid-first.
Biggest risk: energy-led inflation and expectation resets. Invalidation: broad, volume-backed participation plus 10Y below 4.70% would improve risk appetite.
Bias: favor profitable AI infrastructure only after valuation/FCF work; demand commercial proof in quantum and full clinical/runway evidence in biotech.
Biggest risk: persistent inflation, capex digestion, dilution or failed endpoints. Invalidation: durable disinflation plus verified order and FCF acceleration supports more duration exposure.